Stacie Hudgens, CEO of Clinical Outcomes Solutions, on the Effects of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Regimen on Health‐related Quality of Life for Patients with Hepatitis C

COS Stacie Hudgens

Stacie Hudgens, Chief Executive Officer, Strategic Lead Regulatory and Access, at COS, has an article published in Liver International: ‘Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C’

To view this article, please click here.

To find out more about Stacie Hudgens, please click here.